1. Mehanna J, Haddad FG, Eid R, Lambertini M, Kourie HR. Triple-negative breast
cancer: current perspective on the evolving therapeutic landscape. Int J Women Health
(2019) 11:431–7. doi: 10.2147/IJWH.S178349
10. Shima H, Yamada A, Ishikawa T, Endo I. Are breast cancer stem cells the key to
resolving clinical issues in breast cancer therapy? Gland Surg (2017) 6:82–8. doi:
10.21037/gs.2016.08.03
2. Alabdulkareem H, Pinchinat T, Khan S, Landers A, Christos P, Simmons R, et al.
The impact of molecular subtype on breast cancer recurrence in young women treated
with contemporary adjuvant therapy. Breast J (2018) 24:148–53. doi: 10.1111/tbj.12853
11. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF.
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci
U.S.A. (2003) 100:3983–8. doi: 10.1073/pnas.0530291100
3. Fragomeni SM, Sciallis A, Jeruss JS. Molecular subtypes and local-regional control
of breast cancer. Surg Oncol Clin N Am (2018) 27:95–120. doi: 10.1016/
j.soc.2017.08.005
12. Sultan M, Vidovic D, Paine AS, Huynh TT, Coyle KM, Thomas ML, et al.
Epigenetic silencing of TAP1 in aldefluor+ breast cancer stem cells contributes to their
enhanced immune evasion. Stem Cells (2018) 36:641–54. doi: 10.1002/stem.2780
4. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med
(2010) 363:1938–48. doi: 10.1056/NEJMra1001389
13. Li W, Ma H, Zhang J, Zhu L, Wang C, Yang Y. Unraveling the roles of CD44/
CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Sci Rep
(2017) 7:13856. doi: 10.1038/s41598-017-14364-2
5. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast
cancer: Challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol
(2016) 13:674–90. doi: 10.1038/nrclinonc.2016.66
14. Bourguignon LY, Zhu H, Shao L, Chen YW. CD44 interaction with c-src kinase
promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian
tumor cell migration. J Biol Chem (2001) 276:7327–36. doi: 10.1074/jbc.M006498200
6. Lebert JM, Lester R, Powell E, Seal M, McCarthy J. Advances in the systemic treatment
of triple-negative breast cancer. Curr Oncol (2018) 25:S142–50. doi: 10.3747/co.25.3954
15. Fujita Y, Kitagawa M, Nakamura S, Azuma K, Ishii G, Higashi M, et al. CD44
signaling through focal adhesion kinase and its anti-apoptotic effect. FEBS Lett (2002)
528:101–8. doi: 10.1016/S0014-5793(02)03262-3
7. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to
neoadjuvant therapy and long-term survival in patients with triple-negative breast
cancer. J Clin Oncol (2008) 26:1275–81. doi: 10.1200/JCO.2007.14.4147
16. Bazil V, Horejsı́ V. Shedding of the CD44 adhesion molecule from leukocytes
induced by anti-CD44 monoclonal antibody simulating the effect of a natural receptor
ligand. J Immunol (1992) 149:747–3. doi: 10.4049/jimmunol.149.3.747
8. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al.
Residual breast cancers after conventional therapy display mesenchymal as well as
tumor-initiating features. Proc Natl Acad Sci U.S.A. (2009) 106:13820–5. doi: 10.1073/
pnas.0905718106
17. Murakami D, Okamoto I, Nagano O, Kawano Y, Tomita T, Iwatsubo T, et al.
Presenilin-dependent gamma-secretase activity mediates the intramembranous
cleavage of CD44. Oncogen (2003) 22:1511–6. doi: 10.1038/sj.onc.1206298
9. Lee HE, Kim JH, Kim YJ, Choi SY, Kim SW, Kang E, et al. An increase in cancer
stem cell population after primary systemic therapy is a poor prognostic factor in breast
cancer. Br J Cancer (2011) 104:1730–8. doi: 10.1038/bjc.2011.159
Frontiers in Oncology
18. Lu H, Samanta D, Xiang L, Zhang H, Hu H, Chen I, et al. Chemotherapy triggers
HIF-1-dependent glutathione synthesis and copper chelation that induces the breast
13
frontiersin.org
A et al.
10.3389/fonc.2023.1147668
42. Bytautaite M, Petrikaite V. Comparative study of lipophilic statin activity in 2D
and 3D in vitro models of human breast cancer cell lines MDA-MB-231 and MCF-7.
Onco Targets Ther (2020) 13:13201–9. doi: 10.2147/OTT.S283033
cancer stem cell phenotype. Proc Natl Acad Sci U.S.A. (2015) 112:E4600–9. doi:
10.1073/pnas.1513433112
19. Oliveira-Costa JP, Zanetti JS, Silveira GG, Soave DF, Oliveira LR, Zorgetto VA,
et al. Differential expression of HIF-1a in CD44+CD24-/low breast ductal carcinomas.
Diagn Pathol (2011) 6:73. doi: 10.1186/1746-1596-6-73
43. Roybal KT, Williams JZ, Morsut L, Rupp LJ, Kolinko I, Choe JH, et al.
Engineering T cells with customized therapeutic response programs using synthetic
notch receptors. Cell (2016) 167:419–32.e16. doi: 10.1016/j.cell.2016.09.011
20. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al. Hypoxia-inducible
factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 15:501–
13. doi: 10.1016/j.ccr.2009.03.018
44. Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, et al. Precision
tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell (2016)
164:770–9. doi: 10.1016/j.cell.2016.01.011
21. Semenza GL. The hypoxic tumor microenvironment: A driving force for breast
cancer progression. Biochim Biophys Acta (2016) 1863:382–91. doi: 10.1016/
j.bbamcr.2015.05.036
45. Gordon WR, Zimmerman B, He L, Miles LJ, Huang J, Tiyanont K, et al.
Mechanical allostery: Evidence for a force requirement in the proteolytic activation of
notch. Dev Cell (2015) 33:729–36. doi: 10.1016/j.devcel.2015.05.004
22. Vadde R, Vemula S, Jinka R, Merchant N, Bramhachari PV, Nagaraju GP. Role
of hypoxia-inducible factors (HIF) in the maintenance of stemness and malignancy of
colorectal cancer. Crit Rev Oncol Hematol (2017) 113:22–7. doi: 10.1016/
j.critrevonc.2017.02.025
46. Mueller SN, Gebhardt T, Carbone FR, Heath WR. Memory T cell subsets,
migration patterns, and tissue residence. Annu Rev Immunol (2013) 31:137–61. doi:
10.1146/annurev-immunol-032712-095954
23. Kaelin WGJr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the
HIF hydroxylase pathway. Mol Cell (2008) 30:393–402. doi: 10.1016/
j.molcel.2008.04.009
47. Lecourtois M, Schweisguth F. Indirect evidence for delta-dependent intracellular
processing of notch in drosophila embryos. Curr Biol (1998) 8:771–4. doi: 10.1016/
S0960-9822(98)70300-8
24. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving
concept. Nat Rev Cancer (2012) 12:133–43. doi: 10.1038/nrc3184
48. Cho Y, Lee H-W, Kang HG, Kim HY, Kim SJ, Chun KH. Cleaved CD44 intracellular
domain supports activation of stemness factors and promotes tumorigenesis of breast cancer.
Oncotarget (2015) 6:8709–21. doi: 10.18632/oncotarget.3325
25. Liu M, Liu Y, Deng L, Wang D, He X, Zhou L, et al. Transcriptional profiles of
different states of cancer stem cells in triple-negative breast cancer. Mol Cancer (2018)
17:65. doi: 10.1186/s12943-018-0809-x
49. Hamilton SR, Fard SF, Painwand FF, Tolg C, Veiseh M, Wang C, et al. The
hyaluronan receptors CD44 and RHAMM(CD168) from complexes with ERK1,2,
which sustains high basal motility in breast cancer cells. J Biol Chem (2007) 282:16667–
80. doi: 10.1074/jbc.M702078200
26. Kijima T, Osaki T, Nishino K, Kumagai T, Funakoshi T, Goto H, et al.
Application of the cre recombinase/loxP system further enhances antitumor effects
in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer.
Cancer Res (1999) 59:4906–11.
50. Wu M, Cao M, He Y, Liu Y, Yang C, Du Y, et al. A novel role of low molecular
weight hyaluronan in breast cancer metastasis. FASEB J (2015) 29:1290–8. doi: 10.1096/
fj.14-259978
27. Semenza GL. Dynamic regulation of stem cell specification and maintenance by
hypoxia-inducible factors. Mol Asp Med (2016) 47-48:15–23. doi: 10.1016/j.mam.2015.09.004
51. Chaudhuri SR, Mallam JN, Ché vez-Barrios P, Wadhwa L, Ng P, Hurwitz MY,
et al. Modulation of adenoviral transduction in vitro and in vivo by hyaluronan and its
receptor CD44. Mol Ther (2007) 15:566–70. doi: 10.1038/sj.mt.6300044
28. Bai J, Chen WB, Zhang XY, Kang XN, Jin LJ, Zhang H, et al. HIF-2a regulates
CD44 to promote cancer stem cell activation in triple-negative breast cancer via PI3K/
AKT/mTOR signaling. World J Stem Cells (2020) 12:87–99. doi: 10.4252/wjsc.v12.i1.87
52. Sasi W, Jiang WG, Sharma A, Mokbel K. Higher expression levels of SOCS
1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human
breast cancer. BMC Cancer (2010) 10:178. doi: 10.1186/1471-2407-10-178
29. Kopan R, Ilagan MX. The canonical notch signaling pathway: unfolding the
activation mechanism. Cell (2009) 137:216–33. doi: 10.1016/j.cell.2009.03.045
53. Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: A
review. Int J Cancer (2016) 138:2570–8. doi: 10.1002/ijc.29923
30. Yoneda T, Kunimura N, Kitagawa K, Fukui Y, Saito H, Narikiyo K, et al.
Overexpression of SOCS3 mediated by adenovirus vector in mouse and human
castration-resistant prostate cancer cells increases the sensitivity to NK cells in vitro
and in vivo. Cancer Gene Ther (2019) 26:388–99. doi: 10.1038/s41417-018-0075-5
54. Jones KR, Elmore LW, Jackson-Cook C, Demasters G, Povirk LF, Holt SE, et al.
p53-dependent accelerated senescence induced by ionizing radiation in breast tumour
cells. Int J Radiat Biol (2005) 81:445–58. doi: 10.1080/09553000500168549
31. Wang X, Song H, Yu Q, Liu Q, Wang L, Liu Z, et al. Ad-p53 enhances the
sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor
gefitinib. Oncol Rep (2015) 33:526–32. doi: 10.3892/or.2014.3665
55. Shirakawa T, Sasaki R, Gardner TA, Kao C, Zhang ZJ, Sugimura K, et al. Drugresistant human bladder-cancer cells are more sensitive to adenovirus-mediated wildtype p53 gene therapy compared to drug-sensitive cells. Int J Cancer (2001) 94:282–9.
doi: 10.1002/ijc.1453
32. Shona T, Graeme J. A cancer gene therapy approach that targets tumor-associated
hyaluronan. Cancer Growth Metastasis (2009) 2:29–43. doi: 10.4137/CGM.S3716
56. Inoue A, Narumi K, Matsubara N, Sugawara S, Saijo Y, Satoh K, et al.
Administration of wild-type p53 adenoviral vector synergistically enhances the
cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status
of p53 gene. Cancer Lett (2000) 157:105–12. doi: 10.1016/S0304-3835(00)00480-8
33. Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, Thomson M, et al.
Engineering customized cell sensing and response behaviors using synthetic notch
receptors. Cell (2016) 164:780–91. doi: 10.1016/j.cell.2016.01.012
34. Maynard MA, Evans AJ, Hosomi T, Hara S, Jewett MA, Ohh M. Human HIF3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell
carcinoma. FASEB J (2005) 19:191396–406. doi: 10.1096/fj.05-3788com
57. Lin W, Xie J, Xu N, Huang L, Xu A, Li H, et al. Glaucocalyxin a induces G2/M
cell cycle arrest and apoptosis through the PI3K/Akt pathway in human bladder cancer
cells. Int J Biol Sci (2018) 14:418–26. doi: 10.7150/ijbs.23602
35. Iwahori K, Serada S, Fujimoto M, Nomura S, Osaki T, Lee CM, et al.
Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant
pleural mesothelioma. Int J Cancer (2011) 129:1005–17. doi: 10.1002/ijc.25716
58. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, et al. Significance of
macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and
survival in human breast cancer. Clin Cancer Res (2000) 6:3282–9.
36. Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, et al.
Efficient generation of recombinant adenoviruses using adenovirus DNAterminal
protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad
Sci USA (1996) 93:1320–24. doi: 10.1073/pnas.93.3.1320
59. Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, et al. Significant
correlation of monocyte chemoattractant protein-1 expression with neovascularization
and progression of breast carcinoma. Cancer (2001) 92:1085–91. doi: 10.1002/10970142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K
37. Saito H, Kitagawa K, Yoneda T, Fukui Y, Fujsawa M, Bautista D, et al.
Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic
against p53-deleted human prostate cancer cells in vitro. Cancer Gene Ther (2017)
24:289–96. doi: 10.1038/cgt.2017.21
60. Kachamakova-Trojanowska N, Podkalicka P, Bogacz T, Barwacz S, Jó zkowicz A,
Dulak J, et al. HIF-1 stabilization exerts anticancer effects in breast cancer cells in vitro
and in vivo. Biochem Pharmacol (2020) 175:113922. doi: 10.1016/j.bcp.2020.113922
61. Fiebig AA, Zhu W, Hollerbach C, Leber B, Andrews DW. Bcl-XL is qualitatively
different from and ten times more effective than bcl-2 when expressed in a breast cancer
cell line. BMC Cancer (2006) 6:213. doi: 10.1186/1471-2407-6-213
38. Goto H, Osaki T, Kijima T, Nishino K, Kumagai T, Funakoshi T, et al. Gene
therapy utilizing the Cre/loxP system selectively suppresses tumor growth of
disseminated carcinoembryonic antigen-producing cancer cells. Int J Cancer (2001)
94:414–19. doi: 10.1002/ijc.1474
39. Bray S, Musisi H, Bienz M. Bre1 is required for notch signaling and histone
modification. Dev Cell (2005) 8:279–86. doi: 10.1016/j.devcel.2004.11.020
62. Okazaki M, Fushida S, Tsukada T, Kinoshita J, Oyama K, Miyashita T, et al. The
effect of HIF-1a and PKM1 expression on acquisition of chemoresistance. Cancer
Manag Res (2018) 10:1865–74. doi: 10.2147/CMAR.S166136
40. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong
JS, et al. Isolation of a common receptor for coxsackie b viruses and adenoviruses 2 and
5. Science (1997) 275:1320–3. doi: 10.1126/science.275.5304.1320
63. Jiang L, Greenwood TR, Artemov D, Raman V, Winnard PTJr, Heeren RM,
et al. Localized hypoxia results in spatially heterogeneous metabolic signatures in breast
tumor models. Neoplasia (2012) 14:732–41. doi: 10.1593/neo.12858
41. Bernert B, Porsch H, Heldin P. Hyaluronan synthase 2 (HAS2) promotes breast
cancer cell invasion by suppression of tissue metalloproteinase inhibitor 1 (TIMP-1). J
Biol Chem (2011) 286:42349–59. doi: 10.1074/jbc.M111.278598
64. Li Y, He W, Wang R, Yang L, Zhou C, Zhang B. Antitumor effects of
recombinant human adenovirus-p53 against human cutaneous squamous cell
carcinoma in mice. Exp Ther Med (2016) 12:4159–67. doi: 10.3892/etm.2016.3901
Frontiers in Oncology
14
frontiersin.org
...
論文の公開元へ
